IIpca is the 1st company in the world with whom the Clinton Foundation has signed a
partnership agreement for supply of Artesunate 50mg + Amodiaquine 153.1mg Co-blister
tablets at a reduced price to the Clinton Foundation Consortium to ensure wider access.... |
Central Drug Research Institute (CDRI) has entered into a collaborative-cum-license agreement with Ipca for further development of its compound 99/411.... |
In response to the appeal by Dr. Kochi Arata - Director Global Malaria Programme - WHO, Ipca Laboratories Limited is stopping the manufacturing of monotherapies consisting of single ingredient oral Artemisinin derivatives... |
Ipca had conducted clinical trial on b-arteether, before launching it in Indian market.... |
A three-day conference aimed at ensuring a reliable supply
of artemisinin-based combination therapies (ACTs), the most
effective antimalarial medicines currently available, was
held at Arusha... |
| |
| |
